Design, synthesis and evaluation of peptide inhibitors of Mycobacterium tuberculosis ribonucleotide reductase

Journal of Peptide Science

Volumn 13, Issue 12, 2007, Pages 822-832

  Nurbo, Johanna ^a   Roos, Annette K ^a   Muthas, Daniel ^a   Wahlström, Erik ^a   Ericsson, Daniel J ^a   Lundstedt, Torbjörn ^a,b   Unge, Torsten ^a   Karléna, Anders ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b AcurePharma AB   (Sweden)

Author keywords

Alanine scan; FHDoE; Mycobacterium tuberculosis; Peptide inhibitors; Ribonucleotide reductase; Statistical molecular design; Structure activity relationships

Indexed keywords

ALANINE; HEPTAPEPTIDE; PHENYLALANINE; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE INHIBITOR; SYNTHETIC PEPTIDE; TRYPTOPHAN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SALMONELLA TYPHIMURIUM; SOLID PHASE SYNTHESIS;

ANTITUBERCULAR AGENTS; CLONING, MOLECULAR; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION PROFILING; MICROBIAL SENSITIVITY TESTS; MOLECULAR CONFORMATION; MYCOBACTERIUM TUBERCULOSIS; PEPTIDE LIBRARY; PEPTIDES; POLYMERASE CHAIN REACTION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RIBONUCLEOTIDE REDUCTASES; STEREOISOMERISM;

MYCOBACTERIUM TUBERCULOSIS;

EID: 37349063385     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.906     Document Type: Article

References (32)

1. World Health Organization Home Page. http://www.who.int [last accessed Apr 2007].
2. World Health Organization Home Page. http://www.who.int/mediacentre/ factsheets/fs104/en/print.html [last accessed Apr 2007], Fact sheet No 104, March 2007.
3. Thelander L, Reichard P. Reduction of ribonucleotides. Annu. Rev. Biochem. 1979; 48: 133-158.
4. Reichard P. From RNA to DNA, why so many ribonucleotide reductases? Science 1993; 260: 1773-1777.
5. Eriksson M, Uhlin U, Ramaswamy S, Ekberg M, Regnström K, Sjöberg BM, Eklund H. Binding of allosteric effectors to ribonucleotide reductase protein R1: reduction of active-site cysteines promotes substrate binding. Structure 1997; 5: 1077-1092.
6. Larsson A, Sjöberg BM. Identification of the stable free radical tyrosine residue in ribonucleotide reductase. EMBO J. 1986; 5: 2037-2040.
7. Cerqueira NM, Pereira S, Fernandes PA, Ramos MJ. Overview of ribonucleotide reductase inhibitors: an appealing target in antitumour therapy. Curr. Med. Chem. 2005; 12: 1283-1294.
8. Wnuk SF, Robins MJ. Ribonucleotide reductase inhibitors as antiherpes agents. Antiviral Res. 2006; 71: 122-126.
9. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE III, Tekaia F, Badcock D, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krough A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-544.
10. Dawes SS, Warner DF, Tsenova L, Timm J, McKinney JD, Kaplan G, Rubin H, Mizrahi V. Ribonucleotide reduction in Mycobacterium tuberculosis: function and expression of genes encoding class Ib and class II ribonucleotide reductases. Infect. Immun. 2003; 71: 6124-6131.
11. Sassetti CM, Boyd DH, Rubin EJ. Genes required for mycobacterial growth defined by high density mutagenesis. Mol. Microbiol. 2003; 48: 77-84.
12. Climent I, Sjöberg BM, Huang CY. Carboxyl-terminal peptides as probes for Escherichia coli ribonucleotide reductase subunit interaction: kinetic analysis of inhibition studies. Biochemistry 1991; 30: 5164-5171.
13. Yang FD, Spanevello RA, Celiker I, Hirschmann R, Rubin H, Cooperman BS. The carboxyl terminus heptapeptide of the R2 subunit of mammalian ribonucleotide reductase inhibits enzyme activity and can be used to purify the R1 subunit. FEBS Lett. 1990; 272: 61-64.
14. Gaudreau P, Michaud J, Cohen EA, Langelier Y, Brazeau P. Structure-activity studies on synthetic peptides inhibiting herpes simplex virus ribonucleotide reductase. J. Biol. Chem. 1987; 282: 12413-12416.
15. Pender BA, Wu X, Axelsen PH, Cooperman BS. Toward a rational design of peptide inhibitors of ribonucleotide reductase: structure-function and modeling studies. J. Med. Chem. 2001; 44: 36-46.
16. Gaudreau P, Brazeau P, Richer M, Cormier J, Langlois D, Langelier Y. Structure-function studies of peptides inhibiting the ribonucleotide reductase activity of herpes simplex virus type I. J. Med. Chem. 1992; 35: 346-350.
17. Moss N, Deziel R, Adams J, Aubry N, Bailey M, Baillet M, Beaulieu P, DiMaio J, Duceppe JS, Ferland JM, Gauthier J, Ghiro E, Goulet S, Grenier L, Lavallee P, Lepine-Frenette C, Plante R, Rakhit S, Soucy F, Wernic D, Guindon Y. Inhibition of herpes simplex virus type 1 ribonucleotide reductase by substituted tetrapeptide derivatives. J. Med. Chem. 1993; 36: 3005-3009.
18. Yang F, Curran SC, Li IS, Avarbock D, Graf JD, Chua MM, Lu G, Salem J, Rubin H. Characterization of two genes encoding the Mycobacterium tuberculosis ribonucleotide reductase small subunit. J. Bacteriol. 1997; 179: 6408-6415.
19. Barlos K, Gatos D, Kallitsis J, Rapaphotiu G, Sotiriu P, Wenging Y, Schäfer W. Darstellung geschützter peptid-fragmente unter einsatz substituierter triphenylmethyl-harze. Tetrahedron Lett. 1989; 38: 3943-3946.
20. Muthas D, Lek PM, Nurbo J, Karlén A, Lundstedt T. Focused hierarchical design of peptide libraries - follow the lead. J. Chemometrics (in press). DOI: 10.1002/cem. 1069.
21. Bylesjö M, Rantalainen M, Cloarec O, Nicholson JK, Holmes E, Trygg J. OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification, J. Chemom. in press, DOI: 10.1002/cem. 1006.
22. Wold S, Sjöström M, Eriksson L. PLS-regression: a basic tool of chemometrics. Chemom. Intell. Lab. Syst. 2001; 58: 109-130.
23. Trygg J, Wold S. Orthogonal projections to latent structures (OPLS). J. Chemom. 2002; 16: 119-128.
24. Engström Y, Eriksson S, Thelander L, Åkerman M. Ribonucleotide reductase from calf thymus. Purification and properties. Biochemistry 1979; 18: 2941-2948.
25. Cohen EA, Gaudreau PPB, Langelier Y. Specific inhibition of herpesvirus ribonucleotide reductase by a nonapeptide derived from the carboxy terminus of subunit 2. Nature 1986; 321: 441-443.
26. Cornish-Bowden A. Fundamentals of Enzyme Kinetics. Portland Press: London, 2004.
27. Hellberg S, Sjöström M, Skagerberg B, Wold S. Peptide quantitative structure-activity relationships, a multivariate approach. J. Med. Chem. 1987; 38: 1126-1135.
28. Sandberg M, Eriksson L, Jonsson J, Sjöström M, Wold S. New chemical descriptors relevant for the design of biologically active peptides. A multivariate characterization of 87 amino acids. J. Med. Chem. 1998; 41: 2481-2491.
29. Linusson A, Wold S, Norden B. Statistical molecular design of peptoid libraries. Mol. Divers. 1998; 4:103-114.
30. Andersson PM, Lundstedt T. Hierarchical experimental design exemplified by QSAR evaluation of a chemical library directed towards the melanocortin 4 receptor, J. Chemom. 2002; 16: 490-496.
31. Smith GG, Sivakua T. Mechanism of the racemization of amino acids. Kinetics of racemization of arylglycines. J. Org. Chem. 1983; 48: 627-634.
32. Uppsten M, Färnegårdh M, Domkin V, Uhlin U. The first holocomplex structure of ribonucleotide reductase gives new insight into its mechanism of action. J. Mol. Biol. 2006; 359: 365-377.